1、Pharma R&DAnnual Review 2024White PaperLook back at key pipeline trends from the last 12 months so you can forecast success in 2024ContentsWelcome 03Introduction:Total Pipeline Size 05 Pleasant outlook for pharma as things continue to heat up Developing Systems:The 2024 Pipeline by Phase 08 Clin

2、ical development advances still face a stiff headwind Top Companies 11Some enjoy a moment in the sun,but for others the future looks more hazy Therapies and Diseases 19 Cancer still taking R&D by storm Regional Variations 31Where the outlook seems to be brightestMechanisms and Targets 54Immuno-o

3、ncology makes hay while the sun shinesTypes of Pipeline Drugs 59Is the continued move into biotech starting to meet a frosty reception?Whats the Forecast for Pharma?62Plenty of rays of sunshine should hold off any storm clouds on the horizon About the Author 65Pharma R&D Annual Review 2024Copyri

4、ght 2024 Citeline3Welcome to Pharmaprojects 2024 review of trends in pharmaceutical R&D.For over 30 years now,Ive been taking an annual look at the evolution of pharma R&D,and in this article Ill take the temperature of the industry at the start of 2024.Well assess industry trends by examini

5、ng the pipeline by company,therapeutic area,disease,target,and drug type,using data primarily from Pharmaprojects,part of the Citeline suite of products,which has been tracking global drug development since 1980.This report will be followed up by our annual supplement reviewing the New Active Substa

6、nce(NAS)launches for the year just passed.But here,well examine how the pharma R&D climate is changing,look at where the pressure is rising and falling,and try to determine where the outlook is sunny and where storm clouds are gathering.Hopefully,it will help you to take the industrys temperatur